Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have schizophrenia~* Female patients of childbearing potential must be using a medically accepted means of contraception~* Patients must have completed (within 10 days) another IM olanzapine depot study if permitted by that study's protocol.~Exclusion Criteria:~* Patients must not have participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to study entry~* Female patients must not be pregnant or breast-feeding~* Patients must not be experiencing acute, serious or unstable medical conditions other than schizophrenia or schizoaffective disorder~* Patients must not have a substance (except nicotine or caffeine) dependence within the past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- Intramuscular Olanzapine Depot (Type: EXPERIMENTAL): Intramuscular (IM) olanzapine depot flexible dosing and flexible interval

Based on this trial design, predict the completion outcome and termination type (if applicable).